Research Library

This section is being expanded. In the meantime, each product page includes its own list of primary references with DOI links to the original publications.

Retatrutide — Peer-reviewed research

Selected publications on the triple GLP-1 / GIP / glucagon receptor agonist retatrutide, covering clinical trials, structural biology and meta-analyses.

• NEW ENGLAND JOURNAL OF MEDICINE (2023) — Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
  Jastrehoff AM, et al.
  DOI: 10.1056/NEJMoa2301972
• THE LANCET (2023) — Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes — A Phase 2 Trial
  Rosenstock J, et al.
• NATURE MEDICINE (2024) — Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease
  Sanyal AJ, et al.
  DOI: 10.1038/s41591-024-03018-2
• LANCET DIABETES & ENDOCRINOLOGY (2025) — Effects of retatrutide on body composition in people with type 2 diabetes
  Coskun T, et al.
• PUBMED CENTRAL (2025) — Triple Agonism Based Therapies for Obesity
• PUBMED CENTRAL (2025) — Retatrutide — A Game Changer in Obesity Pharmacotherapy
• PUBMED CENTRAL (2025) — Efficacy and safety of retatrutide for obesity treatment: a systematic review and meta-analysis
• ELI LILLY (2025) — TRIUMPH-4 Phase 3 Trial Results
• NATURE CELL DISCOVERY (2024) — Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide
  DOI: 10.1038/s41421-024-00700-0
• PUBCHEM DATABASE — Retatrutide Compound Information
• CLINICALTRIALS.GOV — Retatrutide (LY3437943) Clinical Trials Registry

How to use these references

References are provided for informational and educational purposes only. They do not constitute medical advice and do not imply that the compounds are approved for human or veterinary use.

Suggest a study

Have a publication you'd like us to include? Contact us and we'll review it for the next update.